Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-dose influenza vaccine is an inactivated influenza vaccine formulation that contains four times the amount of hemagglutinin antigen per strain compared to standard-dose vaccines. The increased antigen content is designed to elicit a stronger immune response and provide better protection against seasonal influenza viruses, particularly in older adults whose immune systems may respond less robustly to standard vaccines. The most widely used product is Fluzone High-Dose (including trivalent and quadrivalent formulations), which is indicated for active immunization against disease caused by the included strains of influenza A subtypes and type B viruses. It is administered as a single intramuscular injection (0.7 mL) annually for persons 65 years of age and older. Clinical studies have shown that high-dose formulations are more effective than standard doses at preventing laboratory-confirmed flu and related complications in this population[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on high-dose influenza vaccine.